KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
Yi, Eui-Yeun
KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. [electronic resource] - Experimental & molecular medicine Oct 2006 - 502-8 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1226-3613
10.1038/emm.2006.59 doi
Angiogenesis Inhibitors--pharmacology
Animals
Benzopyrans--pharmacology
Cattle
Cell Movement--drug effects
Cells, Cultured
Endothelial Cells--drug effects
Fibroblast Growth Factor 2--metabolism
Imidazoles--pharmacology
In Vitro Techniques
Ischemia--drug therapy
Male
Matrix Metalloproteinase 2--metabolism
Mice
Mice, Inbred C57BL
Models, Biological
Neovascularization, Pathologic--drug therapy
Neovascularization, Physiologic--drug effects
Receptor, Fibroblast Growth Factor, Type 2--metabolism
Vascular Endothelial Growth Factor Receptor-2--metabolism
KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. [electronic resource] - Experimental & molecular medicine Oct 2006 - 502-8 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1226-3613
10.1038/emm.2006.59 doi
Angiogenesis Inhibitors--pharmacology
Animals
Benzopyrans--pharmacology
Cattle
Cell Movement--drug effects
Cells, Cultured
Endothelial Cells--drug effects
Fibroblast Growth Factor 2--metabolism
Imidazoles--pharmacology
In Vitro Techniques
Ischemia--drug therapy
Male
Matrix Metalloproteinase 2--metabolism
Mice
Mice, Inbred C57BL
Models, Biological
Neovascularization, Pathologic--drug therapy
Neovascularization, Physiologic--drug effects
Receptor, Fibroblast Growth Factor, Type 2--metabolism
Vascular Endothelial Growth Factor Receptor-2--metabolism